GPT and Hepatic fibrosis: The group also successfully demonstrated therapeutic efficacy in a murine model of liver fibrosis, indicated by marked [116] improvements in liver histopathology and a significant reduction in serum levels of hepatic injury biomarkers (alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase), attenuated extracellular matrix (ECM) deposition and reduce the population of α-SMA-positive aHSCs compared to unmodified MSCs, corroborating in vitro findings indicative of inhibited HSC activation.